Zanidatamab (Ziihera, Jazz Pharmaceuticals) as monotherapy is indicated for 'the treatment of adults with unresectable locally advanced or metastatic HER2-positive (IHC3+) biliary tract cancer (BTC) previously treated with at least one prior line of systemic therapy'.
The dosage schedule is available in the summary of product characteristics for zanidatamab.
The list price per pack of 2 vials of 300 mg zanidatamab is currently confidential.
The company has a commercial arrangement. This makes zanidatamab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, Jazz Pharmaceuticals did not disclose its Carbon Reduction Plan for UK carbon emissions.